Journal: Vaccine: X
Article Title: Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study
doi: 10.1016/j.jvacx.2024.100538
Figure Lengend Snippet: The binding antibody against the SARS-CoV-2 RBD in individuals who received a booster with the BA.4/5 bivalent vaccine. A total of 122 enrolled individuals were divided into groups based on the number of the original COVID-19 vaccine they received (2, 3, 4, 5, and 6 doses, respectively) before the booster with the BA.4/5 bivalent Moderna vaccine. Anti-RBD IgG of overall individuals (A) and each group that is categorized based on serostatus of anti-N Ig consisting of negative and positive (B). Serum samples were collected for antibody testing at baseline (0) and 28 days post-vaccination (28). Lines represent the geometric mean titer (GMT) with 95 % confidence intervals (95 % CI). A pairwise comparison displays the geometric mean ratio (GMR) and significant value. The gray area indicates the seronegativity of anti-RBD IgG (<7.1 BAU/mL). A syringe logo indicates individuals with a negative result for anti-N Ig (vaccine alone), while a syringe with a virus logo indicates individuals with a positive result for anti-N Ig (hybrid immunity). The statistical difference was reported as a p -value < 0.05 and no significant difference (ns).
Article Snippet: Additionally, there was no difference in vaccine effectiveness between the Moderna and Pfizer–BioNTech BA.4/5 bivalent boosters .
Techniques: Binding Assay, Comparison, Virus